Glenmark Pharmaceuticals has received final USFDA approval for generic version of Strattera capsules, used in the treatment of attention-deficit/hyperactivity disorder (ADHD). The company has been granted for Atomoxetine capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg. According to industry estimates, Strattera capsules achieved annual sales of approximately $1.1 billion. Currently, the company portfolio consists of 117 products authorised for distribution in the US marketplace and 67 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply